Evidence map›Paper›PMID 28653569›Full record

ReviewImmunotherapy2017

The mutable vaccine for mutable viruses.

Marilia Cascalho, Samuel J Balin, Jeffrey L Platt

Abstract readReview
In one paragraph

Review in Immunotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Marilia CascalhoDepartment of Microbiology & Immunology and Department of Surgery, University of Michigan, Ann Arbor, MI 48109, USA.
Samuel J BalinDepartment of Microbiology & Immunology and Department of Surgery, University of Michigan, Ann Arbor, MI 48109, USA.
Jeffrey L PlattDepartment of Microbiology & Immunology and Department of Surgery, University of Michigan, Ann Arbor, MI 48109, USA.

Funding

Mutable vaccine for biodefenseR21AI061100 · NIAID · MAYO CLINIC · PI CASCALHO, MARILIA ISABEL · 2004 to 2005
$590k
NIAID NIH HHS R21 AI061100
6 · The paper itself

Abstract

Mutable viruses, such as HIV, pose difficult obstacles to prevention and/or control by vaccination. Mutable viruses rapidly diversify in populations and in individuals, impeding development of effective vaccines. We devised the 'mutable vaccine' to appropriate the properties of mutable viruses that undermine conventional strategies. The vaccine consists of a DNA construct encoding viral antigen and regulatory sequences that upon delivery to B cells target the enzymatic apparatus of 'somatic hypermutation' causing the construct to mutate one million-times baseline rates and allowing production and presentation of antigen variants. We postulate the mutable vaccine might thus anticipate diversification of mutable viruses, allowing direct control or slowing of evolution. Initial work presented here should encourage consideration of this novel approach.

Indexed as

AIDS VaccinesAntigens, ViralHIV-1HIV InfectionsMutationVaccines, DNAAnimalsB-LymphocytesHumansSomatic Hypermutation, ImmunoglobulinAIDS VaccinesAntigens, ViralVaccines, DNAantigenB cellescape variantHIVmutable virussomatic hypermutationvaccineviral evolutionvirus

Identifiers

PMID28653569
PMCPMC5619096

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.